TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
TransMedics (Nasdaq: TMDX) reported that on July 29, 2026 it granted non-qualified stock options for an aggregate 18,762 shares and 12,414 restricted stock units to nine new employees as material inducement awards under its Inducement Plan and Nasdaq Listing Rule 5635(c)(4).
The options have a 10-year term, a per-share exercise price of $78.00, and vest 25% after one year with the balance vesting monthly over three years, subject to continued service. RSUs vest 25% on each of the first four anniversaries of employment, also subject to continued service.
Positive
- None.
Negative
- None.
News Explained
The July 29 inducement awards add potential future common-stock issuance, not an immediate transfer of shares: options cover
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 21 | earnings date notice | Neutral | -4.2% | Announcement scheduled second-quarter results and a subsequent investor conference call. |
| Jul 06 | strategic investment | Positive | +3.4% | Completed investment in PAD Aviation to support European transplant logistics expansion. |
| May 21 | inducement grants | Neutral | +0.1% | Granted equity awards to 14 new employees under Nasdaq inducement rules. |
| May 19 | conference presentation | Neutral | +2.8% | Announced participation in the William Blair annual growth stock conference. |
| May 05 | earnings report | Positive | -23.2% | Reported first-quarter revenue and net income while reiterating full-year guidance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Historical reactions were mixed: the stock aligned with strategic and conference-related news but diverged negatively from a scheduling notice and first-quarter results.
Key Terms
non-qualified stock options financial
restricted stock units financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
The stock options were granted with a per share exercise price of
About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Investor Contact:
Brian Johnston
Hannah Jeffrey
332-895-3222
View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302841485.html
SOURCE TransMedics Group, Inc.